Overview

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disorder characterized by recurrent attacks of optic neuritis and myelitis. A strong humoral response with autoantibodies produced by plasma cells (effector B cells) against aquaporin-4 (AQP4) water channels on astrocytes has been identified as the main characteristic of NMOSD physiology. B-cell maturation antigen (BCMA) is expressed on the surface of plasma cells, thus making it an ideal target for targeted therapies. Chimeric antigen receptor (CAR) T cells against BCMA offers another potential therapeutic option to eliminate plasma cells in patients with AQP4-IgG-seropositive NMOSD who still suffer recurrent attacks from conventional treatments. In the current study, the safety and efficacy of a novel CAR-T cell therapy using CT103A cells, are evaluated in patients with relapsed/refractory NMOSD.

Phase:

Early Phase 1

Details

Lead Sponsor:

Tongji Hospital

Collaborator:

Nanjing IASO Biotherapeutics Co.,Ltd

Treatments:

Cyclophosphamide
Fludarabine